uOmnispace.MR vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

uOmnispace.MR

by Shanghai United Imaging Healthcare Co., Ltd.

EchoNext

by Pathway Labs

AI Verdict

uOmnispace.MR and EchoNext both offer AI-powered cardiac diagnostics, but they are not direct competitors due to their distinct input modalities and analytical focus. uOmnispace.MR specializes in advanced post-processing and AI-driven segmentation of MR images for comprehensive analysis across various clinical applications, including cardiac function. In contrast, EchoNext analyzes standard ECGs to detect hidden structural heart disease, such as heart failure and valve disease, providing a non-invasive screening tool.

Choose uOmnispace.MR if…

Choose uOmnispace.MR if your institution requires advanced, AI-powered post-processing and analysis of diverse MR images, including specialized applications for brain, breast, and cardiac imaging. It is ideal for radiologists and specialists who need comprehensive tools for stitching, dynamic studies, spectroscopy, perfusion, and AI-driven cardiac ventricular segmentation to enhance diagnostic workflows.

View uOmnispace.MR →

Choose EchoNext if…

Choose EchoNext if you need a scalable, non-invasive AI screening tool to detect hidden structural heart disease from standard ECGs, particularly in primary care or high-volume settings. It is well-suited for identifying patients at risk for conditions like heart failure, valve disease, and pulmonary hypertension, enabling earlier referral for further diagnostic imaging like echocardiograms.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	uOmnispace.MR	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Software-only medical device; can run standalone or integrated with other cleared applications on standard off-the-shelf PCs; supports remote multi-user access on a network. The broader uOmnispace platform is available as SaaS, on-premise, or hybrid.	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

Both tools are software-only medical devices. uOmnispace.MR is described as a post-processing tool that can run standalone or integrated, supporting remote multi-user access. EchoNext is available through the OpenEvidence clinical decision support platform, suggesting integration into existing workflows. Without specific user experience details or reviews for either, it's difficult to definitively pick a winner in usability.

Clinical Value

EchoNext

EchoNext has demonstrated superior performance in detecting structural heart disease from ECGs compared to cardiologists, even those assisted by AI, and has been validated in multiple studies. A case study even links EchoNext's detection to a patient receiving a heart transplant. uOmnispace.MR's clinical validation focused on demonstrating equivalence and safety for its cardiac ventricular segmentation AI algorithm, with a Dice coefficient of 1.00, but lacks comparative performance data against human experts or impact on patient outcomes.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, with details on implementation fees and annual discounts, making its cost structure clear to potential buyers. uOmnispace.MR only states 'contact for pricing,' which offers no transparency and makes it difficult to assess its value proposition without direct engagement.

Enterprise Readiness

uOmnispace.MR

uOmnispace.MR's deployment options are more flexible, offering standalone, integrated, SaaS, on-premise, or hybrid models, and supporting remote multi-user access. This breadth of deployment options caters to a wider range of enterprise IT infrastructures and preferences. EchoNext is available through a specific clinical decision support platform, which might limit its integration flexibility for some enterprises.

Innovation

EchoNext

EchoNext represents a significant innovation by being the first FDA-cleared AI tool to detect six types of structural heart disease from a standard 12-lead ECG, a traditionally non-diagnostic tool for such conditions. This capability has the potential to create a new screening paradigm for heart disease. uOmnispace.MR offers advanced MR image analysis with AI-driven segmentation, which is valuable but appears to be an enhancement of existing MR post-processing rather than a fundamentally new diagnostic approach.

Support & Docs

Tie

Neither product's provided information or web search results offer specific details about their customer support channels, service level agreements, or the comprehensiveness of their documentation. Without this information, it is not possible to determine a winner for this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	uOmnispace.MR	EchoNext
Name	uOmnispace.MR	EchoNext
Company	Shanghai United Imaging Healthcare Co., Ltd.	Pathway Labs
Description	AI-powered software for comprehensive magnetic resonance (MR) image analysis, supporting diverse clinical applications including brain, breast, and cardiac imaging with advanced post-processing tools and AI-driven segmentation.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Categories	Cardiology AI, Neurology AI, Oncology AI	Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics
Key Features	MR image viewing, processing, and analysis; AI-driven cardiac ventricular segmentation; Stitching for full-format MR images; Dynamic studies analysis; MR Spectroscopy (SVS and CSI); Perfusion analysis (e.g., Brain Perfusion); Vessel analysis for MR vascular images; Cardiac function analysis	AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; FDA-cleared technology; Non-invasive diagnostic support
Target Modality	Magnetic Resonance (MR) images	Standard 12-lead Electrocardiograms (ECGs)

Videos

Demos, reviews, and walkthroughs featuring uOmnispace.MR and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How deeply can uOmnispace.MR and EchoNext integrate with existing EHR systems and clinical workflows?

uOmnispace.MR is a software-only medical device that can run standalone or integrate with other cleared applications, supporting remote multi-user access on a network. The broader uOmnispace platform offers flexible deployment options (SaaS, on-premise, hybrid) and is designed to adapt to various business scenarios, including unimodal, multimodal, departmental, hospital-wide, and remote collaboration, and supports flexible integration with third-party vendors and IT systems. EchoNext is available through the OpenEvidence clinical decision support platform, which aims to embed its screening output directly into existing clinical workflows, rather than requiring a separate system, and OpenEvidence is actively integrating into hospital EHRs.

What is the reported accuracy and sensitivity of each tool in detecting relevant clinical conditions?

uOmnispace.MR's AI-driven cardiac ventricular segmentation algorithm demonstrated a Dice coefficient of 1.00, indicating high consistency and equivalence to predicate devices. EchoNext, trained on over 700,000 ECG-echocardiogram pairs, achieved 77% accuracy in identifying structural heart disease from ECGs alone, outperforming cardiologists (64% accuracy) and even cardiologists assisted by AI (69% accuracy) in studies. It showed high diagnostic accuracy in internal and external validation, maintaining strong performance across diverse patient demographics and clinical settings.

What is the learning curve for physicians adopting uOmnispace.MR versus EchoNext?

While specific learning curve data for uOmnispace.MR is not provided, its comprehensive nature for MR image analysis across various applications suggests a potentially broader learning scope due to its diverse functionalities like MR Spectroscopy and perfusion analysis. EchoNext, as an AI-powered ECG analysis tool, is designed to integrate into routine workflows, and its output is intended to augment clinical decision-making by identifying patients who should receive follow-up echocardiograms, suggesting a potentially more focused learning curve related to interpreting its risk predictions.

What kind of customer support and resources are available for each tool?

For uOmnispace.MR, the company, Shanghai United Imaging Healthcare Co., Ltd., is a global leader in medical imaging and radiotherapy equipment, suggesting a robust infrastructure for support. For EchoNext, its availability through the OpenEvidence platform, which serves over 500,000 physicians nationwide, implies a broad support network through that platform.

How quickly can a practice or hospital expect to see value after implementing uOmnispace.MR or EchoNext?

uOmnispace.MR provides advanced post-processing and AI-driven segmentation for MR images across multiple specialties, which can enhance diagnostic workflows and potentially lead to faster, more efficient image analysis. EchoNext is designed as an early detection and triage tool for structural heart disease, aiming to enable earlier diagnosis, more timely intervention, and improved allocation of imaging resources by identifying high-risk patients from routine ECGs.

What audit trail features do these tools offer to support clinical and administrative oversight?

uOmnispace.MR is a medical image post-processing software that supports viewing, manipulation, annotation, and communication of various medical images, which typically includes features for tracking user actions and changes to images. EchoNext, as an AI tool integrated into a clinical decision support platform, would likely have audit trail capabilities within the OpenEvidence platform to track when and how the AI's predictions are accessed and utilized in patient care.

What are the considerations for rolling out either tool across multiple clinical sites or a large health system?

uOmnispace.MR is a software-only medical device that supports remote multi-user access on a network and can be deployed standalone or integrated, making it adaptable for multi-site rollouts. The broader uOmnispace platform is designed for agile and elastic deployment across various scenarios, including hospital-wide and remote collaboration. EchoNext's partnership with OpenEvidence aims to integrate the tool into real workflows across health systems at a national scale, suggesting a focus on broad accessibility and deployment in both major hospitals and community practices.